September 24, 2021 8:05am

Turning of the tide is a common phrase that references the way the tides are low and high, and the lack of control

Pre-open indications: 0 BUYs and 7 SELLs

What I provide is an intelligence daily. RMi outlines the prelude to the daily dose of facts and objectivity!

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.

Dow futures are DOWN -0.33% (-113 points), S&P futures are DOWN -0.42% (-18 point) and NASDAQ futures are DOWN -0.58% (-88 point)

 

U.S. stock futures were lower on Friday

European stocks were also trading lower,

Asia-Pacific stocks were mixed, although Japan's Nikkei climbed after trading resumed post-holiday

 

Henry’omics:

Yesterday, the stock market rally had another strong session, with the S&P 500 joining the Nasdaq in reclaiming key support while leading stocks showed strong action.

As new records are reached, I say … bye.

 

If you didn’t remember what happen at Thursday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

Q3/21:

  • September, 1 holiday, 9 positive and 6 negative close
  • August - 12 positive and 10 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

Applied Genetic Technologies (AGTC) – reports today, 9/23

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles: WHAT happening in the usual “pump/promote”?

  • Thursday closed up +$0.06 with 839 shares traded after Wednesday closed down -$0.45 with 3,833 shares traded after Tuesday’s +$0.25 with 654 shares traded following Monday closing down -$0.26 to $3.40 with 563 shares traded after last Friday’s 129 shares traded dropping the share price -$0.38 after last Thursday closed -$0.04 with 14,641 shares traded

Question: WERE BSTG’s Q2 filing AUDITED by any accounting firm or left UNAUDITED for investors?

 

SELL from BUY:

Solid Biosciences (SLDB) closed down again -$0.04 to $2.96 after Wednesday’s -$0.20 to $3.00, with a negative -$0.13 or -4.39% pre-market indication as it “finally” report positive 1.5-year functional data and patient-reported outcome measures (Pediatric Outcomes Data Collection Instrument, or PODCI) for patients 4-6 in the ongoing IGNITE DMD P1/2 clinical trial of SGT-001.

CRISP Therapeutics (CRSP) closed up +$3.44 to $121.25 after Wednesday’s +$0.56 to $117.81, Tuesday’s +$0.78 to $117.25, Monday’s down -$8.05 to $116.47 after last Friday’s +$7.10 to $124.52 and has a negative -$2.18 or -1.80% pre-market indication.

Editas Medicine (EDIT) closed up again +$2.96 to $62.07 after Wednesday’s +$0.43 and Tuesday’s $58.68 and Monday’s $58.20 with a negative -$0.57 or -0.92% pre-market indication.

Global Blood Therapeutics (GBT) closed up +$0.38 to $26.52 after Wednesday’s -$0.86 to $26.14, Tuesday’s -$0.10 to $27.00 and Monday’s $27.10 with a negative -$0.97 or -3.66% pre-market indication.

 

Maintaining SELL:

Applied Genetic Technologies (AGTC) closed up +$0.10 to $3.42 after Wednesday’s $, Tuesday’s $ and Monday’s $ with a negative -$0.17 or -4.97% pre-market indication post earnings release

Fate Therapeutics (FATE) closed down -$0.03 to $58.86 after Wednesday’s +$0.76 to $68.89, Tuesday’s +$0.65 to $44.23 and Monday’s $43.58 with a negative -$0.85 or -1.23% pre-market indication,

 

The BOTTOM LINE: I had that “twitch” yesterday – early, concerning the sector’s movement, it will enjoy the ride with the market’s high; however, the wall of worry associated with anxiety and fear need to be considered.

After three (3) up session so far this week, shocks to the sector will probably give us a correction, but these are usually short-lived as the weight of current investment … still needs a home.

I’m … still watching my portfolio’s “six”, it is fraught with the 'turning of the tide" …

Not yielding, I keep reinforcing the theme that increased stock market volatility suppresses the stem, cell and gene therapy sector.

I maintain, the recent stem, cell and gene therapy sector investors should be a bit more defensive, limiting new buys and perhaps curtailing overexposure to electronic trading risks.

Theme is uncertainty, more likely to me: skepticism …

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.